- Home
- JFIN vs PROK Comparison
JFIN vs PROK Comparison
Compare JFIN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFIN | PROK |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.7M | 331.2M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JFIN | PROK |
|---|---|---|
| Price | $4.91 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 48.3K | ★ 635.2K |
| Earning Date | 03-31-2026 | 03-18-2026 |
| Dividend Yield | ★ 14.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $4.97 | $0.46 |
| 52 Week High | $18.70 | $7.13 |
Technical Indicators
Market Signals| Indicator | JFIN | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 26.56 | 32.76 |
| Support Level | N/A | $1.71 |
| Resistance Level | $7.22 | $2.58 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 3.72 | 5.23 |
Price Performance
Historical ComparisonAbout JFIN Jiayin Group Inc.
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.